Kawamoto Hiroyoshi, Latib Azeem, Ruparelia Neil, Ielasi Alfonso, D'Ascenzo Fabrizio, Pennacchi Mauro, Sardella Gennaro, Garbo Roberto, Meliga Emanuele, Moretti Claudio, Rossi Marco Luciano, Presbitero Patrizia, Magri Caroline J, Nakamura Sunao, Colombo Antonio, Boccuzzi Giacomo G
Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy.
EuroIntervention. 2016 Dec 20;12(12):1448-1456. doi: 10.4244/EIJ-D-16-00386.
The aim of this multicentre study was to investigate the in-hospital and midterm outcomes of rotational atherectomy (RA) followed by metallic stent implantation.
Between 2002 and 2013, 1,176 de novo lesions with calcified coronary lesions treated by RA and metallic stent implantation at nine institutions were assessed. Patients with ST-segment elevation myocardial infarction (STEMI) within 30 days, cardiogenic shock before the procedure, lesions with thrombus, and in-stent restenosis were excluded from the current analysis. In-hospital major adverse cardiac events (MACE) occurred in 8.3% of cases, mainly driven by periprocedural myocardial infarction. The incidence of MACE was 16.0% at one-year and 24.9% at two-year follow-up, both driven by target vessel revascularisation (13.5% at one year and 19.8% at two years). Multivariable analysis revealed that dialysis was an independent predictor for both in-hospital MACE (OR 2.33, 95% CI: 1.11-4.87, p=0.03) and follow-up MACE (HR 4.14, 95% CI: 2.87-5.96, p<0.001), whilst drug-eluting stent (DES) use was associated with a reduction in follow-up MACE (HR 0.42, 95% CI: 0.26-0.67, p<0.001).
RA appears to be safe and effective with acceptable in-hospital and follow-up MACE considering the severity of patient and lesion characteristics. DES implantation following RA was associated with a reduction in MACE during the follow-up period.
本多中心研究旨在调查旋磨术(RA)联合金属支架植入后的院内及中期结局。
2002年至2013年期间,对9家机构中1176例接受RA及金属支架植入治疗的新发钙化性冠状动脉病变进行了评估。本次分析排除了30天内发生ST段抬高型心肌梗死(STEMI)、术前发生心源性休克、有血栓形成的病变以及支架内再狭窄患者。8.3%的病例发生了院内主要不良心脏事件(MACE),主要由围手术期心肌梗死所致。随访1年时MACE发生率为16.0%,2年时为24.9%,均由靶血管血运重建所致(1年时为13.5%,2年时为19.8%)。多变量分析显示,透析是院内MACE(OR 2.33,95%CI:1.11 - 4.87,p = 0.03)及随访MACE(HR 4.14,95%CI:2.87 - 5.96,p < 0.001)的独立预测因素,而使用药物洗脱支架(DES)与随访MACE的减少相关(HR 0.42,95%CI:0.26 - 0.67,p < 0.001)。
考虑到患者和病变特征的严重性,RA在院内及随访期间的MACE可接受,似乎是安全有效的。RA后植入DES与随访期间MACE的减少相关。